Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year 2022 Results Conference Call for Thursday, June 30, 2022 at 8:30 AM ET
June 22 2022 - 2:41PM
Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field
Trip"), a global leader in the development and delivery of
psychedelic therapies, announced today that it plans to release
financial results for its fiscal fourth quarter and full year ended
March 31, 2022, after market close on Wednesday, June 29, 2022.
The Company will conduct a conference call and
webcast to discuss its results the following morning, Thursday,
June 30, 2022 at 8:30 a.m. ET. To access the call, please dial
1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the
U.S.) and provide conference ID 13730739. A live webcast of the
conference call can be accessed via the Events and Presentations
section of the Field Trip Health Investor Relations website
here.
For those unable to attend the live call, a
telephonic replay will be available until 11:59 p.m. ET on
Thursday, July 7, 2022. To access the replay dial 1-844-512-2921
(within the U.S.) or 1-412-317-6671 (outside the U.S.) and provide
conference ID 13730739. The webcast will be archived and available
in the Events and Presentations section of the Field Trip Health
Investor Relations website approximately one hour after the
conclusion of the live call.
Nasdaq Notification
The company has also received written
notification (the "Notification
Letter") from The Nasdaq Stock Market LLC
("Nasdaq") notifying the Company that it is not in
compliance with the minimum bid price requirement set forth in
Nasdaq Rules for continued listing on the Nasdaq Global Select
Market. Nasdaq Listing Rules require listed securities to maintain
a minimum bid price of US$1.00 per share, and further
provide that a failure to meet the minimum bid price requirement
exists if the deficiency continues for a period of 30 consecutive
business days. Based on the closing bid price of the Company’s
common shares for the 30 consecutive business days from May 4,
2022, to June 15, 2022, the Company no longer meets the minimum bid
price requirement.
The Notification Letter does not impact the
Company’s listing on the Nasdaq Global Select Market at this time.
In accordance with Nasdaq Listing Rules, the Company has 180
calendar days, or until December 13, 2022, to regain compliance by
virtue of its common shares having a closing bid price of at least
US$1.00 for a minimum of 10 consecutive business days. In the event
the Company does not regain compliance by December 13, 2022, the
Company may be eligible for additional time to regain compliance or
may face delisting.
As previously announced, the Company intends to
consolidate its common shares on a ratio of between 5 and 1
pre-consolidation common share for each pre-consolidation common
share as part of the spin out transaction expected to close in
early August and, therefore, anticipates that the deficiency will
be cured within the prescribed compliance period. The consolidation
is subject to shareholder approval at a special meeting of
shareholders to be held on June 27, 2022.
The Company expects that its common shares will
continue to be listed and trade on the Nasdaq Global Select Market
during these compliance periods. The Company’s business operations
are not affected by the receipt of the Notification Letter. The
Company is also listed on the Toronto Stock Exchange and the
Notification Letter does not affect the Company’s compliance status
with such listing.
For further information concerning the
consolidation, please refer to Field Trip’s management information
circular dated May 20, 2022 and the supplement thereto dated June
14, 2022, each available on the company’s profile on EDGAR and
SEDAR.
About Field Trip Health Ltd.
Field Trip is a global leader in the development
and delivery of psychedelic therapies. With our Field Trip
Discovery division leading the development of the next generation
of psychedelic molecules and conducting advanced research on
plant-based psychedelics and our Field Trip Health division
building centers for psychedelic therapies opening across North
America and Europe along with the digital and technological tools
that will enable massive scale, we help people in need with a
simple, evidence-based way to heal and heighten engagement with the
world.
Learn more at https://www.meetfieldtrip.com,
https://www.fieldtriphealth.com and
https://www.fieldtriphealth.nl.
Follow us on Twitter and Instagram:
@fieldtriphealth.
To receive company updates about Field Trip and
to be added to the email distribution list please sign up here.
Cautionary Note Regarding
Forward-Looking Information
This release includes forward-looking
information (within the meaning of Canadian securities laws and
within the meaning of the United States Private Securities
Litigation Reform Act of 1995) regarding Field Trip and its
business. Often but not always, forward-looking information can be
identified by the use of words such as "expect", "intends",
"anticipated", "believes" or variations (including negative
variations) of such words and phrases, or state that certain
actions, events or results "may", "could", "would" or "will" be
taken, occur or be achieved. Such statements are based on the
current expectations and views of future events of the management
of Field Trip and are based on assumptions and subject to risks and
uncertainties. Although the management of Field Trip believes that
the assumptions underlying these statements are reasonable, they
may prove to be incorrect. The forward-looking events and
circumstances discussed in this release may not occur and could
differ materially as a result of known and unknown risk factors and
uncertainties affecting the companies. Although Field Trip has
attempted to identify important factors that could cause actual
actions, events or results to differ materially from those
described in forward-looking statements, there may be other factors
that cause actions, events or results to differ from those
anticipated, estimated or intended. Accordingly, readers should not
place undue reliance on any forward-looking statements or
information. No forward-looking statement can be guaranteed. Except
as required by applicable securities laws, forward-looking
statements speak only as of the date on which they are made and
Field Trip does not undertake any obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events, or otherwise. Additional information
relating to Field Trip, including its Annual Information Form, can
be located on the SEDAR website at www.sedar.com and on the EDGAR
section of the SEC’s website at www.sec.gov.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy securities.
Neither the Toronto Stock Exchange, nor its
Regulation Services Provider, have approved the contents of this
release or accept responsibility for the adequacy or accuracy of
this release.
CONTACTS:
Investor contacts:Kathleen Heaney / Sophia
BashfordKCSA Strategic CommunicationsfieldtripIR@kcsa.com
Media contacts:Rachel MoskowitzAutumn
Communications202-276-7881press@fieldtriphealth.com
SOURCE Field Trip Health Ltd.
Field Trip Health (TSX:FTRP)
Historical Stock Chart
From Oct 2024 to Nov 2024
Field Trip Health (TSX:FTRP)
Historical Stock Chart
From Nov 2023 to Nov 2024